May 23, 2022 / 05:15PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Good afternoon, everyone. I'm Ellie Merle. Welcome to the UBS Healthcare Conference. Very happy to have Kymera Therapeutics here with us today. Joining us from Kymera is Nello Mainolfi, President and CEO; Bruce Jacobs, Chief Financial Officer; and Jared Gollob, Chief Medical Officer. Thank you guys so much for joining us here today.
Questions and Answers:
Eliana Rachel Merle - UBS Investment Bank, Research Division - AnalystAnd I guess maybe to kick it off before we jump into the programs. High level, what is it about targeted protein degradation that you think is so exciting and potentially disruptive as a novel modality?
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thanks, Ellie. Thanks. Can you guys hear me? I think so. Thanks for inviting us. Actually, this is a great podium here. So let's start with what's not exciting about protein degradation. Now in reality, the opportunities -- we should